CA2196727A1 - Inhibiteur p27kip1 de la kinase cycline-dependante et methode pour reduire la resistance adherence-dependante des cellules tumorales aux agents anticancers - Google Patents

Inhibiteur p27kip1 de la kinase cycline-dependante et methode pour reduire la resistance adherence-dependante des cellules tumorales aux agents anticancers

Info

Publication number
CA2196727A1
CA2196727A1 CA 2196727 CA2196727A CA2196727A1 CA 2196727 A1 CA2196727 A1 CA 2196727A1 CA 2196727 CA2196727 CA 2196727 CA 2196727 A CA2196727 A CA 2196727A CA 2196727 A1 CA2196727 A1 CA 2196727A1
Authority
CA
Canada
Prior art keywords
p27kip1
cells
inhibitor
cell
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2196727
Other languages
English (en)
Inventor
Robert S. Kerbel
Brad B. St. Croix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2196727A1 publication Critical patent/CA2196727A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2196727 1996-09-16 1997-02-04 Inhibiteur p27kip1 de la kinase cycline-dependante et methode pour reduire la resistance adherence-dependante des cellules tumorales aux agents anticancers Abandoned CA2196727A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2614396P 1996-09-16 1996-09-16
US60/026,143 1996-09-16

Publications (1)

Publication Number Publication Date
CA2196727A1 true CA2196727A1 (fr) 1998-03-16

Family

ID=21830151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2196727 Abandoned CA2196727A1 (fr) 1996-09-16 1997-02-04 Inhibiteur p27kip1 de la kinase cycline-dependante et methode pour reduire la resistance adherence-dependante des cellules tumorales aux agents anticancers

Country Status (1)

Country Link
CA (1) CA2196727A1 (fr)

Similar Documents

Publication Publication Date Title
Croix et al. Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
Zhang et al. Inhibitory effects of metformin at low concentration on epithelial–mesenchymal transition of CD44+ CD117+ ovarian cancer stem cells
Kim et al. Current and upcoming mitochondrial targets for cancer therapy
Wu et al. Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal
Cristiano et al. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G2-M phase transition
Fedida-Metula et al. Lipid rafts couple store-operated Ca 2+ entry to constitutive activation of PKB/Akt in a Ca 2+/calmodulin-, Src-and PP2A-mediated pathway and promote melanoma tumor growth
Tao et al. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152
Zhang et al. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma
Fleyshman et al. Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells
Cheng et al. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer
Kanabur et al. Patient-derived glioblastoma stem cells respond differentially to targeted therapies
EP2994155B1 (fr) Ciblage de l'interaction entre un egfr et un sglt1 pour la cancérothérapie
Polo et al. Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice
Lu et al. Autophagy induction of reversine on human follicular thyroid cancer cells
KR20160143775A (ko) iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도
Liu et al. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines
Davis et al. Doxorubicin resistance in breast cancer: a novel role for the human protein AHNAK
WO2017067454A1 (fr) Utilisation pharmaceutique et produit médicamenteux utilisant un inhibiteur de lsd1 pour la prévention et le traitement du cancer du sein triplement négatif
Hsiao et al. Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways
Yuan et al. TIPE3 is a regulator of cell apoptosis in glioblastoma
Sun et al. Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells
Brenet et al. Akt phosphorylation of La regulates specific mRNA translation in glial progenitors
Ahani et al. Genipin induces cell death via intrinsic apoptosis pathways in human glioblastoma cells
Song et al. Knockdown of BCL6 inhibited malignant phenotype and enhanced sensitivity of glioblastoma cells to TMZ through AKT pathway
Shi et al. The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Legal Events

Date Code Title Description
FZDE Dead